Corient Capital Partners’s Integra LifeSciences IART Stock Holding History

Corient Capital Partners’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-5,225	Closed	-$336K	–	720
2022 Q1	$336K	Buy	5,225 +31	+0.6%	+$2.04K	0.02%	502
2021 Q4	$348K	Sell	5,194 -46	-0.9%	-$3.11K	0.02%	465
2021 Q3	$359K	Buy	5,240 +101	+2%	+$7.14K	0.03%	447
2021 Q2	$351K	Buy	5,139 +20	+0.4%	+$1.41K	0.03%	449
2021 Q1	$354K	Buy	+5,119	New	+$347K	0.03%	404

Other funds holding IART

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

EVM

Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Corient Capital Partners's IART Position: Q2 2022 in Review

Corient Capital Partners sold out of Integra LifeSciences (IART) in Q2 2022, closing a stake of 5,225 shares — an estimated $336K sold.

Corient Capital Partners first reported a position in IART in Q1 2021 and held it in 5 quarters. The position peaked at $359K in Q3 2021. 284 funds tracked by Wall St. Rank hold IART as of Q2 2022.

Corient Capital Partners reported no remaining Integra LifeSciences position as of Q2 2022 after selling out during the quarter.
Corient Capital Partners sold 5,225 Integra LifeSciences shares in Q2 2022, an estimated $336K.
Corient Capital Partners first reported a position in Integra LifeSciences in Q1 2021 and held it in 5 quarters.
Corient Capital Partners's Integra LifeSciences position peaked at $359K in Q3 2021.
284 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2022.

Based on Corient Capital Partners's 13F filing for Q2 2022, filed 12 Aug 2022.